Arca
Skip to content
Tools
Tools

MC4R: Melanocortin receptor 4

G protein-coupled receptor that binds melanocyte-stimulating hormones (alpha- and beta-MSH) and corticotropin/ACTH, which are peptide products of the POMC precursor.

  • Drugs that act on it: 3
  • Approved: 2
  • In phases 1 to 3: 1
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on MC4R, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1
  • Protein or peptide 2

Approved2

  • Setmelanotide
  • Bremelanotide

Phase 30

    Phase 21

    • PF-00446687

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Melanocortin receptor 4 agonist.
      SetmelanotideApprovedRhythm PharmaceuticalsProtein or peptideAgonist5
      BremelanotideApprovedCosette PharmaceuticalsProtein or peptideAgonist1
      PF-00446687Phase 2PfizerSmall moleculeAgonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 6 in all, from ClinicalTrials.gov.
      Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic ObesitySetmelanotidePhase 4RecruitingTom HühneJun 29, 2026
      Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)SetmelanotidePhase 2Enrolling by invitationMassachusetts General HospitalMar 27, 2026
      A Study of Setmelanotide in Patients With Prader-Willi SyndromeSetmelanotidePhase 2Active, not recruitingRhythm Pharmaceuticals, Inc.Jan 13, 2025
      A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)SetmelanotidePhase 3RecruitingRhythm Pharmaceuticals, Inc.Jan 7, 2025
      A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of ObesityBremelanotidePhase 2Active, not recruitingPalatin Technologies, IncAug 22, 2024
      A Trial of Setmelanotide in Acquired Hypothalamic ObesitySetmelanotidePhase 3Active, not recruitingRhythm Pharmaceuticals, Inc.Mar 20, 2023

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      Obesity disorder
      0.82
      Abnormality of the skeletal system
      0.73
      Obesity due to melanocortin 4 receptor deficiency
      0.69
      Sexual dysfunction
      0.49
      Bardet-Biedl syndrome
      0.48
      Type 2 diabetes mellitus
      0.47
      Inherited obesity
      0.41
      Overnutrition
      0.40
      Monogenic diabetes
      0.40
      Dentures
      0.39

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL259, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P32245, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.